IRMD is the ticker symbol for IRADIMED CORP, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks IRMD with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is IRMD a good stock to buy?

13F Pro's AI ranking engine scores IRMD at 63.0/100, ranked #655 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for IRMD is available at https://13fpro.ai/company/IRMD. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source IRMD data?

All IRADIMED CORP fundamentals and ownership data come directly from SEC EDGAR. IRADIMED CORP files with the SEC under CIK 1325618. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

IRADIMED CORP IRMD

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #655 of 2,925TOP 25%

Why it scores 63 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$20.47M

Quarter to Jun 30

Net income

$5.22M

Quarter to Jun 30

Free cash flow

$5.75M

Quarter to Jun 30

Operating margin

31.2%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$749.26M total

BlackRock, Inc.

$92.49M0.0%

KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC

$37.94M+13.6%

RENAISSANCE TECHNOLOGIES LLC

$37.69M-10.5%

Copeland Capital Management, LLC

$37.45M+9.1%

VANGUARD CAPITAL MANAGEMENT LLC

$34.87M+1.8%

T. Rowe Price Investment Management, Inc.

$30.45M+24.1%

GEODE CAPITAL MANAGEMENT, LLC

$27.73M+1.2%

Nine Ten Capital Management LLC

$24.52M-23.3%

DIMENSIONAL FUND ADVISORS LP

$21.91M+1.4%

STATE STREET CORP

$21.17M+8.3%

GOLDMAN SACHS GROUP INC

$20.46M+8.2%

TWO SIGMA INVESTMENTS, LP

$17.48M+10.4%

Qube Research & Technologies Ltd

$15.02M+88.4%

ROYAL BANK OF CANADA

$14.16M+397.1%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$13.76M+832.1%

NORTHERN TRUST CORP

$12.77M+8.1%

ACADIAN ASSET MANAGEMENT LLC

$12.29M-15.3%

MORGAN STANLEY

$12.05M-15.9%

VANGUARD PORTFOLIO MANAGEMENT LLC

$11.98M+2.4%

Ranger Investment Management, L.P.

$9.40M-11.5%

Russell Investments Group, Ltd.

$9.08M-4.5%

FIRST TRUST ADVISORS LP

$8.06M+3501.8%

SHAKER INVESTMENTS LLC/OH

$7.80M+36.0%

ENVESTNET ASSET MANAGEMENT INC

$7.51M+4.1%

Bank of New York Mellon Corp

$7.25M-5.0%

See all 214 institutional holders →

What's Driving IRMD's Business? Latest 10-Q Breakdown

25/25 datapoints verified

AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue was essentially flat at $20.5M (+0.5% YoY), but net income fell to $5.2M as gross margin compressed to 74% from 78% on production inefficiencies tied to the new MRidium 3870 pump.

Biggest Revenue Drivers

Devices$13.8M-5% YoY

Decline driven by lower IV infusion pump systems revenue, partially offset by higher patient vital signs monitoring and ferro magnetic detection sales

Disposables$4.8M+14% YoY

Increase attributed in part to modifications to the sales incentive plan

Biggest Revenue Drivers

Total revenue: $20.5M+0.5% YoY

Devices$13.8M-5% YoY

Decline driven by lower IV infusion pump systems revenue, partially offset by higher patient vital signs monitoring and ferro magnetic detection sales

Within Devices

IV Infusion Pump Systems$6.4M-21% YoY

Disposables$4.8M+14% YoY

Increase attributed in part to modifications to the sales incentive plan

Services and other$1.1M+7% YoY

Amortization of extended maintenance agreements$0.8M+28% YoY

Largest Expense Items

Cost of revenue$5.3M+18% YoY

Increase attributed to initial production inefficiencies on new product manufacturing

Sales and marketing$4.2M+6% YoY

Increased sales commissions related to monitor bookings and newly released MRidium 3870 pump bookings

General and administrative$3.9M-9% YoY

Lower legal and professional expenses, regulatory consulting, and payroll and benefit expenses

Research and development$0.7M-22% YoY

Decrease in payroll and benefit expenses capitalized as internal software development for the period

Margins: Gross margin fell to 74% from 78% YoY due to initial production inefficiencies on new product manufacturing; operating margin also declined to 31.3% from 33.3% as gross profit dropped despite lower opex-to-revenue ratio.

Watch Items from the Filing

Gross margin compressed to 74% from 78% YoY due to initial production inefficiencies on new product manufacturing.
US revenue fell 8% YoY to $16.7M while international revenue grew 69% to $3.7M; domestic mix dropped to 82% of revenue from 89%.
IV infusion pump systems revenue declined 21% YoY to $6.4M even as the new MRidium 3870 pump ramps, while vital signs monitoring grew 12%.
Board declared a subsequent quarterly cash dividend of $0.20/share, payable August 28, 2026, continuing the capital return program.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IRMD

Earnings Per Share

13fpro.ai/company/IRMD

Loading ratio trend…

IRADIMED CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$83.8M	$22.5M	31.2%
FY 2024	10-K/A	$73.2M	$19.2M	30.0%
FY 2023	10-K/A	$65.6M	$17.2M	30.6%
FY 2022	10-K	$53.3M	$12.8M	29.3%
FY 2021	10-K	$41.8M	$9.3M	23.5%
FY 2020	10-K	$31.7M	$1.4M	-2.4%

About IRADIMED CORP (IRMD): stock profile, AI score and financials

IRADIMED CORP (IRMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRMD at 63.0/100 on a composite quality score built from its SEC filings, placing it at rank #655 of 2,925 stocks — the top 25% of the AI-ranked universe. IRMD scores in the top quartile across balance sheet strength (96.5), profitability (85.4), free cash flow (83.3). Areas of concern include revenue scale (14.0) and institutional flow (39.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IRADIMED CORP reports quarterly revenue of $20.5M, net income of $5.2M, an operating margin of 31.2%. IRMD trades on the Nasdaq exchange and files with the SEC under CIK 1325618. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IRADIMED CORP directly from SEC EDGAR.

SEC EDGAR: CIK 1325618 →

IRADIMED CORP IRMD

Top Institutional Holders

What's Driving IRMD's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

IRMD key financials by period

About IRADIMED CORP (IRMD): stock profile, AI score and financials